EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

RPG Life Sciences Limited (RPGLIFE) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of RPG Life Sciences Limited ₹436, price ₹2,931, upside -85.1%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · IN · ISIN INE105J01010

RL Thin data Oct 1, 2026

RPG Life Sciences Limited

RPGLIFE · NSE

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value ₹435.85 · Strongly overvalued (−85.1%)
!Quality 52/100
!Expensive Growth (revenue 5y +13.0 %/yr)
✓Solidly profitable · 16.3% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (6/13)
✓Wide moat 70/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 16 out of 100
Watch RPG Life Sciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹3,089 ₹409.99 Fair Value ₹435.85 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range ₹409.99 – ₹3,089 · fair‑value band ₹349.91 – ₹622.98 · the ₹2,931 price screens above the ₹435.85 fair value. Dashed = 300-day average. As of Oct 1, 2026.

Follow RPG Life Sciences in your weekly email

Every Wednesday you see whether RPG Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.

Show more

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

Stock analysis

RPG Life Sciences Limited (RPGLIFE) currently trades at ₹2,931, while our model-based Fair Value estimate is ₹435.85, 85.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹1,296 per share, and 0 of the 17 models we run sit above the ₹2,931 price.

Bear case: the Asset-Based group reads lowest at ₹245.23, and 17 of the 17 models stay below the price. Evidence for this calculation is low.

Scenario range: ₹349.91 (bear) to ₹622.98 (bull), the price of ₹2,931 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

RPG Life Sciences Limited reported revenue of ₹7.1B in FY2026 versus ₹4.4B in FY2022, a compound +12.8%/yr. Reported net income was ₹1.2B in FY2026, compounding +22.3%/yr from FY2022.

Key figures

Market cap ₹48.5B (≈ $503M) · P/E ratio 40.5 · P/S ratio 6.60 · EPS (TTM) ₹72.29 · Dividend yield 0.8% · Net margin 16.3% · Return on equity 20.3% · Return on assets (EBIT) 25.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 5% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −85%, RPGLIFE screens richer than that median.

Fair Value models

Bear ₹349.91 Fair Value ₹435.85 Bull ₹622.98
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹36.64 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings ₹558.28 ₹839.95 ₹1,261 76
EPV ₹526.55 ₹583.66 ₹631.25 74
Residual Income ₹391.05 ₹514.37 ₹805.35 74
All 17 models by family
DCF Models
Owner Earnings ₹558.28 ₹839.95 ₹1,261 76
Earnings-Based
Graham-Dodd ₹473.52 ₹2,070 ₹2,832 64
Lynch FV ₹533.75 ₹762.51 ₹991.26 61
PEG = 1.0 ₹533.75 ₹762.51 ₹991.26 57
EPV ₹526.55 ₹583.66 ₹631.25 74
Dividend Discount
Gordon GGM ₹186.44 ₹335.97 ₹462.50 68
DDM Multi-Stage ₹186.44 ₹306.90 ₹358.90 67
Multiples
P/E Multiple ₹1,149 ₹1,532 ₹1,915 63
P/S Multiple ₹887.85 ₹1,184 ₹1,480 58
P/B Multiple ₹887.85 ₹1,184 ₹1,480 55
EV/EBIT ₹1,076 ₹1,399 ₹1,722 66
EV/EBITDA ₹1,042 ₹1,353 ₹1,664 67
EV/Revenue ₹798.89 ₹1,095 ₹1,391 54
Asset-Based
NCAV (Graham) ₹183.01 ₹245.23 ₹366.01 54
Economic Profit
Residual Income ₹391.05 ₹514.37 ₹805.35 74
ROIC Compounder ₹566.49 ₹688.74 ₹835.94 72
Growth Earnings
Growth-Adj P/E ₹907.20 ₹1,296 ₹1,685 67

Open the full fair value analysis →

Notify me when RPGLIFE reaches fair value

Put RPGLIFE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 52/100

Of which business quality 52 · Market factors (momentum, volatility) 76

Profitability 71
Margins and returns on capital today
Quality Growth 12
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 96
Balance sheet, leverage, solvency risk
Investment 20
Disciplined investing over empire-building
Low Volatility 74
Calm price path (market factor)
Momentum 77
Price trend over the last 3–12 months (market factor)
52W Momentum 78
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Start year 2021 (pandemic). Over 10 years: +9.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+24.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.6%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.6% vs 25.8%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 18%
Start year 2021 (pandemic)

RPGLIFE screens overvalued: fair value 85% below the price. Compare with Merck KGaA →

Compare RPG Life Sciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −85.1% · Bottom 25%
Profitability
Return on equity (TTM) 20.3% · Top 25%
Return on assets 10.8% · Top 25%
Net margin (TTM) 16.3% · Top 25%
Operating margin (TTM) 19.1% · Top 25%
Growth and dividend
Revenue growth 15.8% · Above median
Dividend yield (TTM) 0.8% · Below median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 40.5× · Pricier than median
P/B 8.01× · Priciest 25%
P/S (TTM) 6.60× · Priciest 25%
EV/EBITDA 30.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)79 · sector 24
PAST (return on equity)81 · sector 28
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)16 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.19 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

RPG Life Sciences Limited · Fair Value
₹435.85 −85%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "RPG Life Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/RPGLIFE

Frequently asked questions

Is RPG Life Sciences Limited (RPGLIFE) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹435.85 versus a price of ₹2,931, about −85% upside (overvalued).
What is the fair value of RPGLIFE?
Our model-based fair value for RPG Life Sciences Limited is ₹435.85 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹2,931.
What is the quality score of RPGLIFE?
RPG Life Sciences Limited has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RPG Life Sciences Limited (RPGLIFE)?
Our model-based price target is the fair value of ₹435.85 (as of Oct 1, 2026) from 17 valuation models. Cautious scenario ₹349.91, optimistic scenario ₹622.98. It is a calculation from audited fundamentals, not an analyst target.
What is the RPG Life Sciences Limited stock forecast for 2026?
Our models put fair value at ₹435.85, about −85% upside versus a price of ₹2,931 (overvalued). Cautious scenario ₹349.91, optimistic scenario ₹622.98. The calculation is refreshed regularly with new filings.
What is the revenue of RPG Life Sciences Limited (RPGLIFE)?
RPG Life Sciences Limited reported trailing-twelve-month revenue of about ₹7.3B (latest available figure, as of Oct 1, 2026).
Does RPG Life Sciences Limited pay a dividend?
RPG Life Sciences Limited currently shows a dividend yield of about 0.79% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of RPG Life Sciences Limited (RPGLIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RPG Life Sciences Limited it is ₹435.85 per share (as of Oct 1, 2026), against a price of ₹2,931. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is RPG Life Sciences Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, RPGLIFE trades above its calculated fair value: price ₹2,931, fair value ₹435.85, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RPGLIFE?
No. The price is what the market pays today (₹2,931); the fair value is what the company's own numbers justify (₹435.85). For RPG Life Sciences Limited the two are ₹2,495 per share apart. That gap is exactly why we show both numbers side by side.
How much is RPG Life Sciences Limited worth?
The market values RPG Life Sciences Limited at about ₹48.5B (market capitalisation, as of Oct 1, 2026). Per share that is ₹2,931; our models calculate a fair value of ₹435.85 per share.
What do the bullish and bearish scenarios say about RPGLIFE?
Our models span a range for RPG Life Sciences Limited: cautious scenario ₹349.91, base ₹435.85, optimistic ₹622.98 per share (as of Oct 1, 2026, price ₹2,931). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RPGLIFE?
RPG Life Sciences Limited trades at a price-to-earnings ratio of 40.5 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹435.85 is built from several models across several years. Other multiples: P/B 8.0, P/S 6.6, EV/EBITDA 30.3.
How solid is the balance sheet of RPG Life Sciences Limited (RPGLIFE)?
Balance-sheet figures for RPG Life Sciences Limited (as of Oct 1, 2026): return on equity 20.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is RPGLIFE from its 52-week high?
RPG Life Sciences Limited trades at ₹2,931, about 5% below its 52-week high of ₹3,089 and 68% above the low of ₹1,744 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹435.85 is for.
Which stocks are comparable to RPG Life Sciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RPG Life Sciences Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹2,931, calculated fair value ₹435.85 (−85%), Quality Score 52/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RPGLIFE calculated?
We run RPG Life Sciences Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹435.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. RPG Life Sciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RPG Life Sciences Limited (RPGLIFE)?
The closing price on Oct 1, 2026 was ₹2,931. Our model-based fair value is ₹435.85, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RPG Life Sciences Limited right now?
The price sits above even our optimistic bull case (₹622.98). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of RPG Life Sciences Limited (RPGLIFE) come from?
Earnings per share at RPG Life Sciences Limited grew +31.4 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.9 %, EBIT margin +23.5 %, tax rate −1.9 %, residual (interest, one-offs) −1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of RPG Life Sciences Limited

How large is the market capitalisation of RPG Life Sciences Limited (RPGLIFE)?
The market capitalisation of RPG Life Sciences Limited is ₹48.5B (≈ $503M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RPG Life Sciences Limited (RPGLIFE)?
The price-to-sales ratio of RPG Life Sciences Limited is 6.60 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RPG Life Sciences Limited (RPGLIFE)?
Earnings per share at RPG Life Sciences Limited are ₹72.29 (price ÷ EPS = P/E 40.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of RPG Life Sciences Limited (RPGLIFE)?
The dividend yield of RPG Life Sciences Limited is 0.8% (payout 32.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of RPG Life Sciences Limited (RPGLIFE)?
The net margin of RPG Life Sciences Limited is 16.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RPG Life Sciences Limited (RPGLIFE)?
The return on equity (ROE) of RPG Life Sciences Limited is 20.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RPG Life Sciences Limited (RPGLIFE)?
On an EBIT basis the return on assets of RPG Life Sciences Limited is 25.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RPG Life Sciences Limited (RPGLIFE)?
The operating margin of RPG Life Sciences Limited is 19.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RPG Life Sciences Limited (RPGLIFE)?
Revenue at RPG Life Sciences Limited is growing +15.8% versus a year earlier (3y avg +11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at RPG Life Sciences Limited (RPGLIFE)?
Earnings per share at RPG Life Sciences Limited are growing +17.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does RPG Life Sciences Limited (RPGLIFE) generate?
The free cash flow of RPG Life Sciences Limited is −₹800K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does RPG Life Sciences Limited (RPGLIFE) hold?
RPG Life Sciences Limited holds more cash than debt, ₹1.7B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch RPG Life Sciences Limited in the live analysis

One click puts RPG Life Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.